...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Exploration of the dihydropyrimidine scaffold for the development of new potential anti-inflammatory agents blocking prostaglandin E2 synthase-1 enzyme (mPGES-1)
【24h】

Exploration of the dihydropyrimidine scaffold for the development of new potential anti-inflammatory agents blocking prostaglandin E2 synthase-1 enzyme (mPGES-1)

机译:探索二氢嘧啶骨架以开发新的潜在抗炎药,阻断前列腺素E2合酶-1酶(mPGES-1)

获取原文
获取原文并翻译 | 示例

摘要

Agents targeting microsomal prostaglandin E_2 synthase-1 (mPGES-1) would inhibit only PGE2 production induced by inflammatory stimuli and thus could represent a valuable alternative to non-steroidal anti-inflammatory drugs (NSAIDs) as they should be free from the severe side effects of the classic anti-inflammatory drugs. Although several mPGES-1 inhibitors have been so far identified, none of them is currently in clinical trials, therefore the discovery of new molecular platforms, able to interfere with this interesting target, is urgently required. Here, we report the results of a focused collection of dyhidropyrimidin-2(lH)-one based molecules projected by Virtual Screening computational techniques. The key interactions with the receptor counterpart were introduced as a qualitative filter for the selection of the most promising compounds. The biological data obtained are consistent with the computer-aided suggestions and disclosed two interesting molecules showing in vitro mPGES-1 inhibitory activity in the low muM range.
机译:靶向微粒体前列腺素E_2合酶1(mPGES-1)的药物仅抑制由炎症刺激引起的PGE2产生,因此可以代表非甾体抗炎药(NSAID)的有价值替代品,因为它们应避免严重的副作用经典的抗炎药。尽管到目前为止已经鉴定了几种mPGES-1抑制剂,但目前尚无它们在临床试验中,因此迫切需要发现能够干扰这一有趣靶标的新分子平台。在这里,我们报告由虚拟筛选计算技术投影的基于dyhidropyrimidin-2(lH)-one分子的集中收集的结果。与受体对应物的关键相互作用被引入定性过滤器中,用于选择最有希望的化合物。获得的生物学数据与计算机辅助的建议一致,并公开了两个有趣的分子,它们显示了在低muM范围内的体外mPGES-1抑制活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号